Related Experiment Video
Updated: Mar 15, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Pazopanib does not bring remarkable improvement in patients with angiosarcoma
Shinya Kitamura1, Teruki Yanagi1, Yuka Inamura1
1Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Pazopanib, a tyrosine kinase inhibitor, showed limited efficacy in treating angiosarcoma, with most patients experiencing disease progression or severe side effects. This study suggests pazopanib does not significantly improve outcomes for angiosarcoma patients.
Area of Science:
- Oncology
- Medical Research
Background:
- Pazopanib is a multi-targeted tyrosine kinase inhibitor approved for metastatic soft-tissue sarcoma.
- Its efficacy in cutaneous angiosarcoma remains unconfirmed.
Observation:
- This study retrospectively analyzed eight angiosarcoma cases treated with pazopanib.
- Five patients discontinued treatment due to severe adverse effects like thrombocytopenia, anemia, pancreatitis, and hepatitis.
- Progression-free survival averaged 1.81 months, with six cases showing progressive disease.
Findings:
- Pazopanib treatment did not significantly improve overall survival in angiosarcoma patients compared to a control group.
- The drug demonstrated limited clinical benefit and a high rate of severe adverse events.
Implications:
- Pazopanib is not recommended as a primary treatment for angiosarcoma.
- Further research is needed to identify effective therapies for this rare cancer.
More Related Videos
06:59Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing
Published on: May 12, 2023
12:34Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction
Published on: January 3, 2020
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies